Contineum Therapeutics, Inc. (CTNM) Key Metrics
CTNM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $266.4M
- Enterprise value
- $240.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 11.1
- Price / book
- 2.0
- EV / EBITDA
- 20.8
- Dividend yield
- —
- Beta
- 0.86
CTNM key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCTNM valuation Price multiples at each fiscal year-end price.
CTNM returns How much profit the business earns on the capital it uses.
CTNM per-share figures Results divided by the shares outstanding at year-end.
CTNM financial health Debt, liquidity and how easily interest is covered.
CTNM efficiency & capital use Working capital cycle and where the cash goes.
CTNM valuation history
CTNM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CTNM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CTNM cash returned to shareholders
CTNM price vs earnings per share
CTNM key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $316.6M | $378.8M | — | — | — |
| Enterprise value | $62.0M | $180.3M | — | — | — |
| Price / book | 1.2 | 1.9 | — | — | — |
| Earnings yield | −18.9% | −11.2% | — | — | — |
| Free cash flow yield | −17.5% | −8.8% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — | — |
| Share price at fiscal year-end | $11.43 | $14.65 | — | — | — |
| Per share | |||||
| Revenue per share | $0.00 | $0.00 | $1.99 | $0.00 | $0.00 |
| Earnings per share | −$2.17 | −$1.63 | $0.90 | −$0.97 | −$1.15 |
| Operating cash flow per share | −$2.00 | −$1.27 | $0.77 | −$0.80 | −$1.05 |
| Free cash flow per share | −$2.01 | −$1.29 | $0.75 | −$0.81 | −$1.05 |
| Cash per share | $9.49 | $7.92 | $4.98 | $1.88 | $2.75 |
| Book value per share | $9.42 | $7.66 | −$2.70 | $1.56 | $2.45 |
| Tangible book value per share | $9.42 | $7.66 | −$2.70 | $1.56 | $2.45 |
| Capex per share | $0.01 | $0.02 | $0.02 | $0.00 | $0.01 |
| Debt per share | $0.30 | $0.24 | $7.69 | $0.23 | $0.20 |
| Shares outstanding | 27.7M | 25.9M | 25.1M | 25.1M | 25.1M |
| Change in shares outstanding | +7.1% | +2.9% | 0.0% | 0.0% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −26.1% | −64.9% | — | −48.1% | −47.1% |
| Return on assets (ROA) | −24.5% | −24.6% | 25.1% | −40.0% | −41.1% |
| Return on tangible assets | −21.7% | −19.9% | 17.4% | −47.9% | −41.1% |
| Free cash flow margin | — | — | 37.9% | — | — |
| Income quality (OCF / net income) | — | — | 0.85 | — | — |
| Financial health | |||||
| Total debt | $8.2M | $6.3M | $193.2M | $5.8M | $4.9M |
| Cash & short-term investments | $262.9M | $204.8M | $125.2M | $47.2M | $69.0M |
| Net debt | −$254.6M | −$198.5M | $68.0M | −$41.4M | −$64.1M |
| Debt / equity | 0.03 | 0.03 | — | 0.15 | 0.08 |
| Debt / assets | 0.03 | 0.03 | 1.48 | 0.12 | 0.07 |
| Net debt / EBITDA | — | — | 2.88 | — | — |
| Current ratio | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Quick ratio | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Interest coverage | — | — | -77.3 | -58.6 | -86.3 |
| Working capital | $258.2M | $196.4M | $122.2M | $40.8M | $66.1M |
| Invested capital | $6.3M | −$435,000 | $66,000 | −$2.1M | −$2.5M |
| Tangible asset value | $261.0M | $198.1M | −$67.9M | $39.3M | $61.6M |
| Net current asset value | $252.3M | $191.6M | −$70.6M | $37.0M | $60.8M |
| Graham net-net per share | $8.93 | $7.35 | −$2.91 | $1.43 | $2.39 |
| Capital allocation | |||||
| Share buybacks (net) | — | $0 | $28,000 | $4,000 | $0 |
| Dividends + buybacks / free cash flow | — | — | 0.1% | — | — |
| Capex / revenue | — | — | 0.8% | — | — |
| Capex / operating cash flow | — | — | 2.1% | — | — |
| Capex / depreciation | 0.72 | 1.99 | 2.12 | 0.36 | 0.52 |
| Stock-based compensation / revenue | — | — | 4.4% | — | — |
| R&D / revenue | — | — | 55.2% | — | — |
| SG&A / revenue | — | — | 13.0% | — | — |
| Efficiency | |||||
| Days payables outstanding | 1,597.3 | 1,730.2 | 996.7 | 604.6 | — |
| Payables turnover | 0.23 | 0.21 | 0.37 | 0.60 | — |
| Asset turnover | 0.00 | 0.00 | 0.55 | 0.00 | 0.00 |
| Average payables | $1.4M | $1.2M | $532,500 | $545,000 | $660,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CTNM's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CTNM valuation and financial ratios
Contineum Therapeutics earned a return on equity of −26.1% in fiscal 2025. It ended the year with $8.2 million of debt and $262.9 million in cash and short-term investments, a net cash position of $254.6 million. The share count rose 10.2% from 25.1M to 27.7M over 4 years.
See the CTNM income statement, the CTNM chart for price history, or the CTNM stock overview for the latest quote and news.
CTNM key metrics FAQ
What is Contineum Therapeutics's return on equity?
Contineum Therapeutics's return on equity (ROE) was −26.1% in fiscal 2025: net income of -$60.0 million on average shareholders' equity of $229.5 million.
How much debt does Contineum Therapeutics have?
Contineum Therapeutics had total debt of $8.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Contineum Therapeutics's free cash flow yield?
Contineum Therapeutics generated -$55.5 million of free cash flow in fiscal 2025, a free cash flow yield of −17.5% on its market value at year-end ($316.6 million).
What is Contineum Therapeutics's current ratio?
Contineum Therapeutics's current ratio was 27.50 at the end of fiscal 2025: current assets were 27.50 times current liabilities.